Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells
Keywords: Dopamine; Lung cancer; VEGF; Cabergoline; Angiogenesis; Dopamine D2 receptor agonists; D2R; dopamine D2 receptor; LLC1; Lewis lung carcinoma 1; NSCLC; non-small cell lung cancer; VEGF; vascular endothelial growth factor A; EGFR; epidermal growth factor re